Sponsored: The Science of Treating Social Impairment in Autism
Understanding the Study
The purpose of this study is to learn if the study medication may improve social functioning in 18-30 year old adults with autism spectrum disorder and high brain glutamate compared to placebo. Participants who qualify with social impairment and high brain glutamate based on a brain scan would be randomly assigned to receive either EM-113 or placebo.
About the Study Medication
EM-113 is a novel form of memantine, an FDA-approved NMDA antagonist drug which is already known to be generally safe and well-tolerated in adults with Alzheimer’s disease. It is taken as a capsule once daily.
Autism Spectrum Disorder
So far, there are no approved medications for people with autism, although an imbalance in regulation of brain glutamate may be related to social impairment. An NMDA antagonist may restore glutamate equilibrium without causing new and serious side effects.
Interested in learning more?
If you are interested in learning more about the study and finding a study site near you, please go to our study website here. New sites are opening all the time, so please check back periodically.
About Us
Science
EuMentis is developing noncompetitive, low-trapping glutamate antagonists designed to inhibit receptors on neurons that are overly active. EuMentis is combining this clinically-validated approach with novel imaging technology to identify patients with autism spectrum disorder who are most likely to benefit.
Our Mission
We apply a 21st century, integrated understanding of brain science to create and test novel and better therapies that are urgently needed. We aim to seek new solutions to difficult problems with compassion, creativity and optimism.
See our website here https://www.eumentistx.com/EM-113 Study
Noncompetitive low-trapping NMDA antagonists
EuMentis is developing noncompetitive, low-trapping glutamate antagonists designed to inhibit receptors on neurons that are overly active. EuMentis is combining this clinically-validated approach with novel imaging technology to identify patients with autism spectrum disorder who are most likely to benefit.